8:30a ET 11/8/2022 – Dow Jones
*Avenue Therapeutics Completes The Acquisition Of Baergic Bio And Its Selective GABA-A 2/3 Receptor Positive Allosteric Modulator For The Treatment Of Central Nervous System Disorders >ATXI
Mentioned: ATXI
8:30a ET 11/8/2022 – Dow Jones
*Avenue Therapeutics Completes The Acquisition Of Baergic Bio And Its Selective GABA-A 2/3 Receptor Positive Allosteric Modulator For The Treatment Of Central Nervous System Disorders >ATXI
Mentioned: ATXI
Leave a Reply